Sandra Ortega-Francisco

Dr. Sandra Ortega-Francisco

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
FCFlavia Chiuppesi
Flavia Chiuppesi
JZJohn A. Zaia
John A. Zaia
MGMiguel-Angel Gutierrez-Franco
Miguel-Angel Gutierrez-Franco
SOSandra Ortega-Francisco
Sandra Ortega-Francisco
MLMinh Ly
Minh Ly
DDDon Diamond
Don Diamond
Background: Although the mpox global health emergency caused by mpox virus (MPXV) clade IIb.1 has ended, mpox cases are still reported due to low vaccination coverage and waning immunity. COH04S1 is a clinically evaluated, multiantigen COVID-19 vaccine candidate built on a fully synthetic platform of the highly attenuated modified vaccinia Ankara (MVA) vector, representing the only FDA-approved smallpox/mpox vaccine JYNNEOS. Given the potential threat of MPXV resurgence and need for vaccine alternatives, we aimed to assess the capacity COH04S1 and its synthetic MVA (sMVA) backbone to confer MPXV-specific immunity. Methods: We evaluated orthopoxvirus-specific and MPXV cross-reactive immune responses in samples collected during a Phase 1 clinical trial of COH04S1 and in non-human primates (NHP) vaccinated with COH04S1 or its sMVA backbone. MPXV cross-reactive immune responses in COH04S1-vaccinated healthy adults were compared to responses measured in healthy subjects vaccinated with JYNNEOS. Additionally, we evaluated the protective efficacy of COH04S1 and sMVA against mpox in mpox-susceptible CAST/EiJ mice. Results: COH04S1-vaccinated individuals develop robust orthopoxvirus-specific humoral and cellular responses, including cross-reactive antibodies to MPXV-specific virion proteins as well as MPXV cross-neutralizing antibodies in 45% of the subjects. In addition, NHP vaccinated with COH04S1 or sMVA show similar MPXV cross-reactive antibody responses. Moreover, MPXV cross-reactive humoral responses elicited by COH04S1 are comparable to those measured in JYNNEOS-vaccinated subjects. Finally, we show that mice vaccinated with COH04S1 or sMVA are protected from lung infection following challenge with MPXV clade IIb.1. Conclusions: These results demonstrate the capacity of sMVA vaccines to elicit cross-reactive and protective orthopox-specific immunity against MPXV, suggesting that COH04S1 and sMVA could be developed as bivalent or monovalent mpox vaccine alternatives against MPXV.

27 September 2022 in Vaccine
Verified
Journal Article
Closed access
JCJacquelynne Cervantes
Jacquelynne Cervantes
SRSergio Rosales-Mendoza
Sergio Rosales-Mendoza
CCCARLOS CABELLO-GUTIERREZ
CARLOS CABELLO-GUTIERREZ
LMLaura Montero
Laura Montero
JAJuan Alberto Hernandez Aceves
Juan Alberto Hernandez Aceves
ESEdda Sciutto
Edda Sciutto

15 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
FCFlavia Chiuppesi
Flavia Chiuppesi
SOSandra Ortega-Francisco
Sandra Ortega-Francisco
MGMiguel-Angel Gutierrez
Miguel-Angel Gutierrez
JLJing Li
Jing Li
MLMinh Ly
Minh Ly
SDSanjeet Dadwal Dadwal
Sanjeet Dadwal Dadwal
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination. As part of the safety lead-in portion of a phase 2 clinical trial in patients post HCT/CAR-T for hematological malignancies (HM), we tested the immunogenicity of the synthetic modified vaccinia Ankara-based COVID-19 vaccine COH04S1 co-expressing spike (S) and nucleocapsid (N) antigens. Thirteen patients were vaccinated 3–12 months post HCT/CAR-T with two to four doses of COH04S1. SARS-CoV-2 antigen-specific humoral and cellular immune responses, including neutralizing antibodies to ancestral virus and variants of concern (VOC), were measured up to six months post vaccination and compared to immune responses in historical cohorts of naïve healthy volunteers (HV) vaccinated with COH04S1 and naïve healthcare workers (HCW) vaccinated with the FDA-approved mRNA vaccine Comirnaty® (Pfizer, New York, NY, USA). After one or two COH04S1 vaccine doses, HCT/CAR-T recipients showed a significant increase in S- and N-specific binding antibody titers and neutralizing antibodies with potent activity against SARS-CoV-2 ancestral virus and VOC, including the highly immune evasive Omicron XBB.1.5 variant. Furthermore, vaccination with COH04S1 resulted in a significant increase in S- and N-specific T cells, predominantly CD4+ T lymphocytes. Elevated S- and N-specific immune responses continued to persist at six months post vaccination. Furthermore, both humoral and cellular immune responses in COH04S1-vaccinated HCT/CAR-T patients were superior or comparable to those measured in COH04S1-vaccinated HV or Comirnaty®-vaccinated HCW. These results demonstrate robust stimulation of SARS-CoV-2 S- and N-specific immune responses including cross-reactive neutralizing antibodies by COH04S1 in HM patients post HCT/CAR-T, supporting further testing of COH04S1 in immunocompromised populations.

29 August 2025 in FEBS Open Bio
Verified
Journal Article
Open access
SOSandra Ortega-Francisco
Sandra Ortega-Francisco
RORoxana Olguín‐Alor
Roxana Olguín‐Alor
LBLizbeth Bolaños‐Castro
Lizbeth Bolaños‐Castro
AMAlexandra Morales‐Cruz
Alexandra Morales‐Cruz
MFMarisol De La Fuente‐Granada
Marisol De La Fuente‐Granada
GSGloria Soldevila
Gloria Soldevila
Our group has previously reported that inhibin and its molecular pair, TGF‐β type III receptor (TβRIII), regulate T cell development within the thymus. In addition, inhibins play a key role in immune tolerance through the modulation of dendritic cell (DC) maturation and peripheral Treg induction. However, the functional role of inhibins in T cell activation and differentiation is currently unknown. Here, we demonstrate that inhibins are produced by activated T cells and play a role during T cell activation, migration, and functional Th differentiation. Specifically, stimulation of Inhα −/− naïve T cells resulted in decreased expression of early activation markers, including CD69, CD25, and TβRIII, compared to Inhα +/+ T cells. Additionally, we analyzed the migratory potential of Inhα −/− T cells toward CCR7 ligands and showed an impaired in vitro chemotaxis toward CCL21 and CCL19, which correlated with a decreased homing to peripheral lymph nodes using in vivo competitive assays. To evaluate the impact of inhibins on Th differentiation, we performed in vitro polarization cultures under skewing conditions. Interestingly, Inhα −/− naïve T cells showed a decreased differentiation to Th1 cells, while the induction of Th17 cells was significantly increased when compared with Inhα +/+ . This preferential polarization of Inhα −/− toward Th17 was reversed by the addition of recombinant Inh A, without altering the differentiation of Inhα −/− Th1. Our data demonstrate that inhibins regulate T cell effector differentiation and homing and thus, may be considered new players in T cell immune responses.

14 September 2026 in Journal of Infection
Verified
Journal Article
Open access
SOSandra Ortega-Francisco
Sandra Ortega-Francisco
MAMaria Teresa Prudente de Aquino
Maria Teresa Prudente de Aquino
FCFlavia Chiuppesi
Flavia Chiuppesi
MGMiguel-Angel Gutierrez-Franco
Miguel-Angel Gutierrez-Franco
CRCorinna La Rosa
Corinna La Rosa
DDDon Diamond
Don Diamond